Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Xenon Pharmaceuticals Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, CA [1] - The presentation will be led by Ian Mortimer, President and CEO, and will be available via live audio webcast [2] Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of therapeutics for patients in need [3] - The company's lead molecule, azetukalner, is a selective Kv7 potassium channel opener currently in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD) [3] - Xenon is also developing an early-stage portfolio of potassium and sodium channel modulators, including Kv7 and NaV1.7 programs in Phase 1 for potential pain treatment [3]